<DOC>
	<DOCNO>NCT00348985</DOCNO>
	<brief_summary>This phase I trial study side effect best dose PXD101 bortezomib treat patient advance solid tumor lymphomas . PXD101 bortezomib may stop growth cancer cell block enzymes need cell growth . PXD101 may also cause cancer cell look like normal cell , grow spread slowly . Giving PXD101 together bortezomib may kill cancer cell .</brief_summary>
	<brief_title>PXD101 Bortezomib Treating Patients With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate safety profile determine maximum tolerate dose PXD101 combination bortezomib patient advance solid tumor lymphomas . II . Determine pharmacokinetics combination PXD101 bortezomib patient . III . Evaluate select biomarkers drug effect patient . IV . Evaluate activity regimen , term objective response rate , patient . OUTLINE : This dose-escalation study . Patients receive PXD101 IV 30 minute day 1-5 bortezomib IV day 1 , 4 , 8 , 11 ( 2 , 5 , 8 , 11 course 1 ) . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-9 patient receive escalate dos bortezomib PXD101 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Blood collect baseline periodically course 1 study treatment pharmacokinetic study . After completion study treatment , patient follow periodically 4 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically cytologically confirm solid tumor lymphoma refractory standard therapy standard therapy exist No active , untreated , symptomatic brain metastasis Patients treat brain metastasis eligible provided metastasis stable patient steroid anticonvulsant ECOG performance status 02 Life expectancy ≥ 12 week WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( 5 time ULN presence liver metastasis ) Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction attribute compound similar chemical biologic composition PXD101 , bortezomib , boron , mannitol No peripheral neuropathy &gt; grade 1 No uncontrolled intercurrent illness , include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Psychiatric illness social situation would preclude study requirement No significant cardiovascular disease , include follow : Myocardial infarction within past 6 month New York Heart Association class IIIIV heart failure Unstable angina pectoris Uncontrolled hypertension Condition require antiarrhythmic therapy Ischemic severe valvular heart disease Acute ischemia active conduction system abnormality ECG No mark baseline prolongation QT/QTc interval ( repeat demonstration QTc interval &gt; 500 msec ) , long QT syndrome , require use concurrent medication PXD101 administration may cause torsade de point No severe medical psychiatric problem would preclude study compliance At least 4 week since prior chemotherapy ( 6 week nitrosoureas , carmustine , mitomycin C ) At least 4 week since prior radiotherapy recover At least 2 week since prior palliative radiotherapy sit involve &lt; 35 % bone marrow reserve At least 4 week since prior investigational agent At least 2 week since prior valproic acid histone deacetylase inhibitor No prior stem cell bone marrow transplantation No concurrent radiotherapy immunotherapy No concurrent hormonal therapy Luteinizing hormonereleasing hormone agonist , selective estrogen receptor modulators , aromatase inhibitor chronic maintenance therapy allow No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>